NCT06196580 - PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2024

Primary Completion Date

February 16, 2024

Study Completion Date

February 16, 2024

Conditions

Gout and Hyperuricemia

Interventions

DRUG

repaglinide; midazolam; SHR4640

DRUG

repaglinide; midazolam; SHR4640; SHR4640 placebo

DRUG

repaglinide; midazolam; SHR4640 placebo

Trial Locations (1)

The Second Hospital of Anhui Medical University, Hefei

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY